The National Council is examining the cost effects of cannabis in medicine
Potential for lower healthcare costs
Many patients report that they have been able to reduce or even completely discontinue other medications thanks to cannabis-based medicines. At the same time, many experience improvements in their quality of life, sleep quality, and, in some cases, their ability to work. However, these potential cost savings and economic benefits have so far received little systematic investigation.
Access is expensive
Although doctors have been allowed to prescribe cannabis-based medicines without special authorization since 2022, most patients have to pay for their treatment themselves. An estimated 10,000 people in Switzerland rely on cannabis-based medicines, while only around 70 receive reimbursement from their health insurance. Significant price differences between pharmacies further increase the financial burden for patients.
MEDCAN welcomes the examination
We expressly welcome this initiative. For years, those affected have reported that cannabis-based medicines not only alleviate symptoms but can also often reduce the need for other medications. A scientifically sound analysis of the actual costs and benefits is therefore long overdue.